New study tests medications for brain symptoms in three genetic disorders

NCT ID NCT00768820

Recruiting now Disease control Sponsor: The Chaim Sheba Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at thinking and mental health issues in people with Velocardiofacial, Williams, and Fragile X syndromes. Researchers will test how well medications like methylphenidate, fluoxetine, and risperidone improve these symptoms. The goal is to better understand and treat these conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: methylphenidate, fluoxetine, risperidone
What this could lead to: If successful, this could help identify which medications best manage psychiatric and cognitive symptoms in these genetic syndromes.
What could go wrong: This is a Phase 4 study with a small, specific population, so results may not apply broadly. Medications may cause side effects or not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRAGILE X SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

DiGeorge syndrome fragile X syndrome velocardiofacial syndrome Williams syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FRAGILE X SYNDROME VELOCARDIOFACIAL SYNDROME WILLIAMS SYNDROME

Contacts and locations

Locations

Schneider Children's Mediac Center of Israel
RECRUITING

Petah Tikva, 49202, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.